These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19248137)

  • 1. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.
    Jin J; Yang JY; Liu J; Kong YY; Wang Y; Li GD
    World J Gastroenterol; 2002 Jun; 8(3):505-10. PubMed ID: 12046080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies.
    Verstrepen BE; Depla E; Rollier CS; Mares G; Drexhage JA; Priem S; Verschoor EJ; Koopman G; Granier C; Dreux M; Cosset FL; Maertens G; Heeney JL
    J Infect Dis; 2011 Sep; 204(6):837-44. PubMed ID: 21849281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination.
    Clarke JL; Paruch L; Dobrica MO; Caras I; Tucureanu C; Onu A; Ciulean S; Stavaru C; Eerde A; Wang Y; Steen H; Haugslien S; Petrareanu C; Lazar C; Popescu CI; Bock R; Dubuisson J; Branza-Nichita N
    Plant Biotechnol J; 2017 Dec; 15(12):1611-1621. PubMed ID: 28419665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses.
    Lee SW; Cho JH; Lee KJ; Sung YC
    Mol Cells; 1998 Aug; 8(4):444-51. PubMed ID: 9749532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging cancer vaccines: the promise of genetic vectors.
    Aurisicchio L; Ciliberto G
    Cancers (Basel); 2011 Sep; 3(3):3687-713. PubMed ID: 24212974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.
    Huret C; Desjardins D; Miyalou M; Levacher B; Amadoudji Zin M; Bonduelle O; Combadière B; Dalba C; Klatzmann D; Bellier B
    Vaccine; 2013 Mar; 31(11):1540-7. PubMed ID: 22634300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical applications for exosomes: Are we there yet?
    Perocheau D; Touramanidou L; Gurung S; Gissen P; Baruteau J
    Br J Pharmacol; 2021 Jun; 178(12):2375-2392. PubMed ID: 33751579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family.
    Wong SH; Jassey A; Wang JY; Wang WC; Liu CH; Lin LT
    Vaccines (Basel); 2019 Sep; 7(4):. PubMed ID: 31547131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudotyping retrovirus like particles vaccine candidates with Hepatitis C virus envelope protein E2 requires the cellular expression of CD81.
    Soares HR; Castro R; Tomás HA; Carrondo MJT; Alves PM; Coroadinha AS
    AMB Express; 2019 Feb; 9(1):22. PubMed ID: 30729353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.
    Masavuli MG; Wijesundara DK; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Microbiol; 2017; 8():2413. PubMed ID: 29259601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.
    Torresi J
    Front Microbiol; 2017; 8():2163. PubMed ID: 29163442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-
    Courau T; Nehar-Belaid D; Florez L; Levacher B; Vazquez T; Brimaud F; Bellier B; Klatzmann D
    JCI Insight; 2016 Jun; 1(9):e85974. PubMed ID: 27699271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.
    Lener T; Gimona M; Aigner L; Börger V; Buzas E; Camussi G; Chaput N; Chatterjee D; Court FA; Del Portillo HA; O'Driscoll L; Fais S; Falcon-Perez JM; Felderhoff-Mueser U; Fraile L; Gho YS; Görgens A; Gupta RC; Hendrix A; Hermann DM; Hill AF; Hochberg F; Horn PA; de Kleijn D; Kordelas L; Kramer BW; Krämer-Albers EM; Laner-Plamberger S; Laitinen S; Leonardi T; Lorenowicz MJ; Lim SK; Lötvall J; Maguire CA; Marcilla A; Nazarenko I; Ochiya T; Patel T; Pedersen S; Pocsfalvi G; Pluchino S; Quesenberry P; Reischl IG; Rivera FJ; Sanzenbacher R; Schallmoser K; Slaper-Cortenbach I; Strunk D; Tonn T; Vader P; van Balkom BW; Wauben M; Andaloussi SE; Théry C; Rohde E; Giebel B
    J Extracell Vesicles; 2015; 4():30087. PubMed ID: 26725829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T-cell development and function are impaired in mice lacking membrane expression of full length intercellular adhesion molecule-1.
    Gottrand G; Courau T; Thomas-Vaslin V; Prevel N; Vazquez T; Ruocco MG; Lambrecht B; Bellier B; Colombo BM; Klatzmann D
    Immunology; 2015 Dec; 146(4):657-70. PubMed ID: 26370005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of early diagnosis in patients with maxillary sinus carcinoma.
    Kreppel M; Safi AF; Scheer M; Nickenig HJ; Zöller J; Preuss S; Meyer M; Rothamel D; Dreiseidler T
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2629-35. PubMed ID: 26345241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain.
    Ou W; Delisle J; Jacques J; Shih J; Price G; Kuhn JH; Wang V; Verthelyi D; Kaplan G; Wilson CA
    Virol J; 2012 Jan; 9():32. PubMed ID: 22273269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.
    Alekseeva E; Sominskaya I; Skrastina D; Egorova I; Starodubova E; Kushners E; Mihailova M; Petrakova N; Bruvere R; Kozlovskaya T; Isaguliants M; Pumpens P
    Genet Vaccines Ther; 2009 Jun; 7():7. PubMed ID: 19505299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.
    Desjardins D; Huret C; Dalba C; Kreppel F; Kochanek S; Cosset FL; Tangy F; Klatzmann D; Bellier B
    J Gene Med; 2009 Apr; 11(4):313-25. PubMed ID: 19248137
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.